Ligands directed against integrin and uses thereof
Patent Information
- Application Number
- DE602019078060
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-04-27
- Filing Date
- 2019-04-29
- Publication Date
- 2025-11-12
- Estimated Expiration
- 2039-04-29
AI Technical Summary
There is a need for stable and effective targeting compounds that can selectively bind to integrin alpha-v beta-3 and alpha-v beta-5 to facilitate the delivery of therapeutic cargo molecules, such as oligonucleotide-based compounds, to specific cells or tissues, particularly tumor cells, as existing inhibitors like Cilengitide have shown limited efficacy in clinical trials.
Development of integrin targeting ligands that exhibit affinity for integrin alpha-v beta-3 and alpha-v beta-5, which are conjugated to cargo molecules like RNAi agents, enabling selective delivery to cells expressing these integrins, thereby inhibiting target gene expression and treating diseases like clear cell renal carcinoma.
The integrin targeting ligands provide stable and specific delivery of therapeutic cargo molecules to integrin-expressing cells, effectively inhibiting target gene expression and treating various cancers in vivo.